



Prospective Studies – in mUM

1. Van den Hoek L., Burgmans M., Tong T., et al.

Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol.* 2026 Mar;27(3):372-382. doi: 10.1016/S1470-2045(25)00720-X.

2. Zager J. S., Orloff M. M., Ferrucci P. F., et al.

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open Label, Single Arm, Multicenter Phase 3 Study. *Pubmed.ncbi.nlm.nih.gov/38704501/*

3. Zager J. S., Orloff M. M., Ferruci P. F., et al.

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. *Journal of Cancer Research and Clinical Oncology* (2026) 152:25 <https://doi.org/10.1007/s00432-025-06291-x>.

4. Zager J. S., Orloff M. M., Ferrucci P. F., et al.

An open-label, randomized study of melphalan/hepatic delivery system versus best alternative care in patients with unresectable metastatic uveal melanoma. *Ann Surg Oncol.* 2025;32(7):4976–88. <https://doi.org/10.1245/s10434-025-17231-x>.

5. Meijer T. S., Burgmans M. C., de Leede E. M., et al.

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. *Ann Surg Oncol* (2021) 28:1130–1141; doi.org/10.1245/s10434-020-08741-x.

6. Meijer T. S., Burgmans M. C., Fiocco M., et al.

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. *Cardiovasc Intervent Radiol* (2019) 42:841–852; doi.org/10.1007/s00270-019-02177-x.

Prospective Studies – in mUM *continued*

7. Tong T. M. L., Burgmans M. C., Speetjens F. M., et al.

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. *Cardiovasc Intervent Radiol*; doi.org/10.1007/s00270-022-03338-1.

Quality of Life Data – in mUM

8. Vigneswarana G., Malalasekera W., Smith V., et al.

Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma. *Melanoma Res*; DOI: 10.1097/CMR.0000000000000947.

9. Tong T. M. L., Fiocco M., van Duijn-de Vreugd J. J., et al.

Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases. *Cardiovasc Intervent Radiol*; doi.org/10.1007/s00270-024-03713-0.

Retrospective Studies – long-term data in mUM

10. Reiner C. M., Schneider M. A., Weilert H., et al.

Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center Experience. *Cancers* 2025, 17, 3834. <https://doi.org/10.3390/cancers17233834>.

11. Laukhuf J., Wiens L., Grözinger G., et al.

Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021. *Int J Cancer.* 2025;1-7. doi:10.1002/ijc.70246, <https://pubmed.ncbi.nlm.nih.gov/41216869/>

Retrospective Studies – comparative in mUM

- 12.** Kolb M., Forschner A., Artzner C., et al.
Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. *Cancers* 2023, 15(20), 4942; doi.org/10.3390/cancers15204942.

Retrospective Studies – safety and efficacy (in mUM)

- 13.** Wiens L., Grözinger G., Dittmann H., et al.
Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021. *Ther Adv Med Oncol* 2024, Vol. 16: 1–12; <https://doi.org/10.1177/17588359241273020>.
- 14.** Ghali H., Dugan M. M., Aflatooni S., et al.
Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma. *Ann Surg Oncol* 2024; <https://doi.org/10.1245/s10434-024-16039-5>.
- 15.** Tong T. M. L., Samim M., Kapiteijn E., et al.
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis. *Cardiovasc Intervent Radiol* (2022) 45:1304–1313.

Retrospective Studies – safety and efficacy (in mUM) *continued*

- 16.** Artzner C., Mossakowski O., Hefferman G., et al.
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver dominant metastatic uveal melanoma: a single center experience. *Cancer Imaging* (2019) 19:31; doi.org/10.1186/s40644-019-0218-4.
- 17.** Brüning R., Tiede M., Schneider M., et al.
Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden. *Radiology Research and Practice*, Volume 2020, Article ID 5672048, 7 pages; doi.org/10.1155/2020/5672048.
- 18.** Dewald C. L. A., Warnke M., Brüning R., et al.
Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. *Cancers* 2022, 14(1), 118; doi.org/10.3390/cancers14010118.
- 19.** Modi S., Gibson T., Vigneswaran G., et al.
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. *Melanoma Research* 32(2):p 103-111, April 2022; DOI: 10.1097/CMR.0000000000000806.



Retrospective Studies – anaesthesia topics

- 20.** Rehn P., Tan B., Turra J., et al.
Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer. *Cancers* 2024, 16, 3698. <https://doi.org/10.3390/cancers16213698>.
- 21.** Metze M., Zimmermann S., Kirsten H., et al.
Effects of Protamine Reversal on Coagulation Parameters After High-Dose Heparin Administration in Percutaneous Hepatic Chemosaturation Intervention. *Clinics and Practics* 2025, 15, 38; doi.org/10.3390/clinpract15020038.

Review Articles in mUM

- 22.** Padia S., A., Modi S., Wehrenberg-Klee E., et al.
Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion. *J Vasc Interv Radiol* 2026; 37:107887; <https://doi.org/10.1016/j.jvir.2025.10.018>

Retrospective Studies – mUM and other indication

- 23.** Veelken R., Ebel S., Schindler A., et al.
Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation. *ESMO Gastrointestinal Oncology*, Volume 5 Issue C 2024; <https://doi.org/10.1016/j.esmogo.2024.100082>.
- 24.** Vogel A., Ochsenreither S., Zager J. S., et al.
Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. *Cancer Treatment Reviews*; doi.org/10.1016/j.ctrv.2022.102501.

Retrospective Studies – mUM and other indication *continued*

- 25.** Veelken R., Maiwald B., Strocka S., et al.
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. *Cardiovasc Intervent Radiol* (2022) 45:218–222; doi.org/10.1007/s00270-021-02983-2.
- 26.** Schönfeld L., Hinrichs J. B., Marquardt S., et al.
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. *Journal of Cancer Research and Clinical Oncology* (2020) 146:3003–3012; doi.org/10.1007/s00432-020-03289-5.
- 27.** Marquardt S., Kirstein M. M., Brüning R., et al.
Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. *European Radiology*; doi.org/10.1007/s00330-018-5729-z.
- 28.** Dewald C. L. A., Becker L. S., Maschke S. K., et al.
Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. *Clinical & Experimental Metastasis* (2020) 37:683–692; doi.org/10.1007/s10585-020-10057-9.



